.jpg)
- Cancer biotherapy & radiopharmaceuticals
-
影響因子：
1.738
-
I S S N：
1084-9785
-
出 版 社：
Mary Ann Liebert, Inc
-
出 版 地：
Larchmont, NY
-
出版國家：
United States
-
刊 期：
雙月刊
-
創(chuàng)刊時(shí)間：
1996
-
語 種：
英文
-
審稿周期：
平均3月
-
中科院分區(qū)：
4
-
投稿命中率：
命中率約95%
-
國外數(shù)據(jù)庫收錄：
IM
-
中國收錄文章數(shù)：
153
-
5年影響因子：
1.685
-
研究領(lǐng)域：
生物制劑、腫瘤、核醫(yī)學(xué)
-
官方鏈接：
http://online.liebertpub.com/cbr
-
投稿須知：
http://online.liebertpub.com/cbr
期刊介紹：
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
Cancer Biotherapy and Radiopharmaceuticals coverage includes:
Antibody drug conjugates
Fusion toxins and immunotoxins
Nanoparticle therapy
Vascular therapy
Inhibitors of proliferation signaling pathways
Cancer Biotherapy and Radiopharmaceuticals is under the editorial leadership of Editors Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham; Robert K. Oldham, MD, Lower Keys Cancer Center; and other leading investigators. View the entire editorial
